Month: September 2026

Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer

HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that new data on its lead drug candidate, Annamycin (naxtarubicin), will be presented at three scientific venues in September 2026, including the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development.

The three presentations address distinct questions about Annamycin: where it concentrates in the body, how it kills cancer cells, and whether it can also enlist the immune system to do so. Together they inform the Company’s development of Annamycin in hard-to-treat cancers.

Title: “Antitumor activity of ANNAMYCIN, a highly effective lipophilic DNA-binding drug: Impact of its organotropism”
Author/Presenter: Waldemar Priebe, PhD, UT MD Anderson Cancer Center
Congress: XIII Congress of the Polish Medical Diaspora
Dates: September 9–12, 2026
Location: Wroclaw, Poland

Annamycin’s lipophilic structure drives it to concentrate in specific tissues rather than distribute uniformly. Dr. Priebe’s presentation examines how that distribution relates to the antitumor activity observed across preclinical models, and what it may mean for treating tumors in those tissues.

Title: “Organotropism-guided exploration of anticancer properties of Annamycin (naxtarubicin), a potent topoisomerase II targeting agent”
Author/Presenter: Waldemar Priebe, PhD, UT MD Anderson Cancer Center
Event: Invited Lecture at the Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
Date: September 14, 2026
Location: Wroclaw, Poland

This invited lecture extends the same line of inquiry to mechanism, examining how Annamycin’s tissue distribution interacts with its inhibition of topoisomerase II, the enzyme target through which anthracyclines produce DNA damage in dividing cells.

Title: “Turning cold pancreatic tumors hot: Antitumor activity of Annamycin is partially mediated by CD8+ T cell cytotoxicity”
Author/Presenter: Angela T. Alistar, MD, Morristown Medical Center, Atlantic Health System / Carol G. Simon Cancer Center
Congress: AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development
Dates: September 25–28, 2026
Location: Hilton San Diego Bayfront, San Diego, California

The abstract for this presentation remains under embargo until publication. Moleculin expects to report on the findings when the abstract is published, as described below.

Abstracts selected for presentation at the AACR Conference on Pancreatic Cancer will be published as a supplement to the September 15, 2026 issue of Cancer Research on September 25, 2026, at 1:00 p.m. ET.

“Annamycin’s ability to concentrate in specific tissues is one of the properties that most distinguishes it from currently prescribed anthracyclines, and it is the through-line across these presentations,” said Walter Klemp, Chairman, President and Chief Executive Officer of Moleculin. “Having this work presented by leading investigators, and accepted at an AACR conference, reflects the breadth of scientific interest in Annamycin beyond our lead indication in AML.”

These presentations run alongside Moleculin’s lead clinical program, the ongoing MIRACLE trial evaluating AnnAraC in patients with relapsed or refractory acute myeloid leukemia (AML). MIRACLE remains the Company’s primary development focus and the basis of its near-term milestones.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML and the expectation that interim efficacy trends observed in a limited patient population will be confirmed in the full study population (the interim results presented are based on a small sample size (n=45), have not achieved statistical significance, and may not be predictive of results from the completed trial). Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

Acquisition Adds 55 MW of Contracted Power Capacity, including 15 MW Energized at Closing, Expanding AIB’s Total Contracted Portfolio from 65 MW to 120 MW

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — AIB Data Centers Inc. (NYSE American: AIB) (“AIB” or the “Company”), a developer and operator of digital infrastructure focused on artificial intelligence (“AI”) and high-performance computing (“HPC”) workloads, today announced the completion of a strategic acquisition of two adjacent parcels totaling approximately 29.4 acres in Texas. The acquisition increases AIB’s total contracted power capacity from 65 megawatts (“MW”) to 120 MW.

The site comprises a 5.0-acre parcel with 15 MW of energized service and an existing building shell, together with an adjacent 24.4-acre parcel carrying 40 MW of contracted service under a new facilities extension agreement, with the additional capacity currently under development. With the additional capacity secured, AIB’s commercial focus remains on converting its portfolio into long-term AI and HPC customer contracts, and the Company is in active discussions with prospective tenants.

AIB funded the approximately $11.2 million closing payment from cash on hand, with the $6.0 million deferred balance secured by a standby letter of credit issued by JPMorgan Chase Bank, allowing the Company to complete the acquisition without shareholder dilution or third-party debt financing. AIB closed the quarter ended June 30, 2026 with a strengthened financial position, including $52.8 million in cash, $82.7 million in stockholders’ equity, and no traditional debt.

Access to energized power remains a principal constraint on the deployment of AI and HPC infrastructure. The 15 MW in service at closing, together with the existing building shell, is expected to shorten the timeline from acquisition to deployment, while the additional 40 MW under development provides a defined path to expand capacity on the same footprint. The site’s approximately 55 MW of planned aggregate capacity is below the 75 MW threshold ERCOT and the Public Utility Commission of Texas use to classify “Large Loads” under the state’s large-load interconnection framework, including the Batch Zero process, while remaining subject to applicable utility, interconnection and regulatory requirements.

“Power is the gating constraint in AI infrastructure, and energized capacity with existing infrastructure is increasingly scarce,” said Jerry Tang, Chief Executive Officer of AIB Data Centers. “This acquisition expands our contracted power portfolio while adding a strategically located, scalable asset to our development portfolio. We believe the combination of available power, existing infrastructure, and additional contracted capacity can meaningfully compress the timeline from land acquisition to customer deployment while creating a strong foundation for future AI and HPC projects.”

About AIB Data Centers

AIB Data Centers Inc. is a developer and operator of digital infrastructure focused on AI hosting and high-performance computing workloads. The Company’s platform combines access to reliable, scalable power resources with modular infrastructure deployment designed to accelerate the development of next-generation compute capacity.

For more information, visit https://www.aib.us/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the development and energization of additional electrical capacity at the site in Texas, the anticipated timing of capacity deployment, the applicability and impact of utility and regulatory requirements, and the Company’s development pipeline and growth strategy. These statements are based on management’s current expectations and are subject to risks and uncertainties, including the timing and completion of utility construction and interconnection work, changes in applicable laws, regulations or utility requirements, the availability of capital, customer demand, and other factors described in the Company’s filings with the Securities and Exchange Commission. Actual results may differ materially. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Investor Relations

Chris Tyson
Executive Vice President
MZ Group – MZ North America
Phone: (949) 491-8235
AIB@mzgroup.us
www.mzgroup.us

PARIS and NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — Pasqal (Nasdaq: PSQL), a global leader in neutral-atom quantum computing, today announced the date for the release of its financial results for the first half of 2026, covering the six months ended June 30, 2026, and its participation in upcoming investor conferences.

First Half 2026 Earnings Call

Pasqal will report its first half 2026 financial results before the open of U.S. financial markets on Thursday, September 24, 2026. Pasqal will host a conference call with the financial community that day at 8:00 a.m. Eastern Time to discuss the results. A live webcast and archived replay of the call will be available on Pasqal’s investor relations website. To access the conference call by phone, please dial 1-877-497-9071 (U.S. and Canada) or 1-201-689-8727 (international).

Upcoming Investor Conferences

Wasiq Bokhari, Chief Executive Officer, and Stéphane Rougeot, Chief Financial Officer, will participate in the following upcoming investor conferences:

• Tuesday, October 13, 2026 – Jefferies European Disruptive Tech Conference in London.
• Wednesday, October 21, 2026 – Goldman Sachs Disruptive Technology Symposium in Paris.

Investors interested in scheduling meetings with Pasqal should contact their respective conference representatives.

Contacts

Investors
investors@pasqal.com

Media
pr@pasqal.com

About Pasqal

Pasqal (Nasdaq: PSQL) helps organizations tackle problems that are difficult or impossible to solve with conventional computing methods alone. Founded in 2019 on Nobel Prize–winning research, Pasqal builds and operates neutral-atom quantum computers, delivered with a full software stack, for industry, science, and governments. Pasqal’s production-ready systems are available both on-premises and through the cloud, enabling organizations to harness quantum computing without requiring in-house quantum expertise. A single hardware platform supports analog workloads today and is designed to evolve toward fault-tolerant quantum computing in the future.

Headquartered in France with operations globally, Pasqal’s quantum computing systems are used by customers across energy, financial services and advanced materials to address complex challenges. Pasqal’s customers include Saudi Aramco, Crédit Agricole CIB, LG Electronics and supported by partnerships with NVIDIA and IBM (Pasqal is part of the IBM Quantum Network). 

NEWARK, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) — IDT Corporation (NYSE: IDT), a global provider of fintech and communications solutions, has scheduled its report of financial and operational results for the fourth quarter and full fiscal year 2026 (the three and twelve months ended July 31, 2026) on Monday, September 28, 2026.

IDT’s earnings release will be issued and posted on the IDT investor relations website (https://www.idt.net/investors-and–media) at approximately 4:30 PM Eastern.

IDT will host an earnings conference call beginning at 5:30 PM Eastern with management’s discussion of results followed by Q&A with investors. To listen to the call and participate in the Q&A, dial 1- 888-506-0062 (toll-free from the US) or 1-973-528-0011 (international) and provide the following access code: 266780.

A replay of the conference call will be available approximately three hours after the call concludes through October 12, 2026. To access the call replay, dial 1-877-481-4010 (toll-free from the US) or 1-919-882-2331 (international) and provide this replay passcode: 54497. The replay will also be accessible via streaming audio at the IDT investor relations website.

ABOUT IDT CORPORATION

IDT Corporation (NYSE: IDT) is a global provider of fintech, communications and AI-powered customer experience solutions through a portfolio of synergistic businesses: National Retail Solutions’ (NRS) point-of-sale (POS) platform enables independent retailers to process transactions and operate more effectively while providing advertisers and marketers with reach into underserved consumer markets; BOSS Money facilitates innovative international remittances and fintech payments solutions; net2phone provides businesses with AI-driven workflow and communications solutions to enhance customer experience;  BOSS Revolution  makes sharing prepaid products and services and speaking with friends and family around the world convenient and reliable; and, IDT Global and IDT Express enable communications companies to provision and manage international voice and SMS messaging.

Contact:
Bill Ulrey
IDT Investor Relations
Phone: (973) 438-3838
E-mail: invest@idt.net

###

Following years of proven success with a top-three U.S. life insurer, ID Dataweb will now expand the use of Trust Stamp’s proprietary IT2 tokenization technology across its existing and prospective customer base

ATLANTA, GA, Sept. 14, 2026 (GLOBE NEWSWIRE) — Trust Stamp (Nasdaq: IDAI), a global provider of AI-powered identity and privacy-enhancing technologies, today announced a major expansion of its strategic partnership with ID Dataweb™, a recognized leader in identity threat detection and risk mitigation. Building on three years of joint success serving one of the three largest life insurance providers in the United States, ID Dataweb will expand its use Trust Stamp’s biometric tokenization and identity fraud mitigation capabilities across its growing enterprise customer base.

The expanded relationship builds on a proven enterprise deployment and creates a scalable path for broader adoption of Trust Stamp’s technology through ID Dataweb. Trust Stamp’s patented Irreversibly Transformed Identity Token (IT2) technology transforms sensitive biometric data into secure, revocable identity tokens, helping organizations reduce the risks associated with storing biometric data while supporting privacy-conscious identity verification and fraud mitigation.

Trust Stamp President Andrew Gowasack commented, “Our long-standing work with ID Dataweb and a leading U.S. life insurance provider has demonstrated the technical and operational value of our technology in a demanding enterprise environment. Expanding our relationship with ID Dataweb represents an important next step in our commercial growth strategy and creates an opportunity to bring our IT2 technology to a broader range of enterprise customers. By combining Trust Stamp’s privacy-preserving tokenization capabilities with ID Dataweb’s identity threat detection platform and established enterprise reach, we can help more organizations strengthen identity trust while reducing the risks associated with sensitive biometric data.”

“Our relationship with Trust Stamp demonstrates the value of bringing together innovative, privacy-preserving technologies to solve real-world identity challenges,” said Matt Cochran, Chief Operating Officer at ID Dataweb. “After three years of successfully deploying Trust Stamp’s technology in a demanding enterprise environment, we see a significant opportunity to extend these capabilities to a broader set of customers. By integrating Trust Stamp’s biometric tokenization technology into the ID Dataweb platform, we can give organizations another powerful tool to establish identity trust, mitigate identity threats, and protect sensitive biometric information without introducing unnecessary friction into the customer experience.”

About Trust Stamp
Trust Stamp is a global provider of AI-powered services for use in multiple sectors including banking and finance, regulatory compliance, government, healthcare, real estate, communications, and humanitarian services. Its technology empowers organizations via advanced solutions that reduce fraud, tokenize and secure assets and data, and securely authenticate users while protecting personal privacy, reducing friction in digital transactions, and increasing operational efficiency. With team members from over twenty nationalities in ten countries across North America, Europe, Asia, and Africa, Trust Stamp trades on the Nasdaq Capital Market (Nasdaq: IDAI).

About ID Dataweb
ID Dataweb™ helps enterprises stay ahead of identity fraud and account-related threats with real-time detection and mitigation while maintaining a seamless experience for their workforce, third parties, and customers. The ID Dataweb SaaS platform combines adaptive identity verification methods, behavioral analytics, device and credential intelligence, and risk scoring. Backed by AI and expert insights, these capabilities proactively stop identity-based attacks, protect revenue, and strengthen compliance. Unlike static legacy identity tools, ID Dataweb delivers dynamic, multi-layered risk orchestration that adapts to evolving threats. Its low-code, cloud-native services deploy quickly, integrate seamlessly with existing IAM systems, and align with each customer’s policies.

ID Dataweb originated from the National Strategy for Trusted Identities in Cyberspace (NSTIC) initiative in 2011, which aimed to establish a user-centric digital ecosystem based on secure, privacy-preserving, and interoperable credentials rather than usernames and passwords. ID Dataweb’s founders brought this vision to market as a leading private-sector enabler of NSTIC. Today, ID Dataweb is a trusted partner to Fortune 1000 companies processing hundreds of millions transactions. Many leading identity security providers such as RSA, Ping Identity, CyberArk (now part of Palo Alto Networks), Okta, Auth0, Saviynt, and SailPoint partner with ID Dataweb to embed the company’s technology into their solutions or ensure seamless interoperability. In a world where digital trust is the new currency, robust identity threat detection and risk mitigation is no longer just a security measure it is a business imperative. That is where ID Dataweb makes a difference. For more information, please visit www.iddataweb.com.

Safe Harbor Statement: Caution Concerning Forward-Looking Remarks
All statements in this release that are not based on historical fact are “forward-looking statements” including within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The information in this announcement may contain forward-looking statements and information related to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events-based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.

Inquiries:
Trust Stamp: shareholders@truststamp.ai

Base Integration Marks Imperium’s First Expansion Beyond Ethereum Mainnet

WAYNE, Pa., Sept. 14, 2026 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), short for Blockchain Technology Consensus Solutions, a company focused on decentralized finance and blockchain infrastructure operations, today announces that Imperium, the Company’s decentralized finance (“DeFi”) business line, has expanded onto Base, an Ethereum Layer-2 network created by Coinbase. Base runs on top of Ethereum and is designed to make transactions faster and cheaper, which has helped it become one of the most widely used blockchain networks.

“We continue to explore new opportunities that we believe can generate scalable high-margin revenue, and expanding Imperium into a multi-chain strategy is a clear example of that. Operating across multiple networks and assets lets us dynamically provide liquidity where volume and demand shift, and Base is our first step beyond Ethereum mainnet,” said Charles Allen, CEO of BTCS. “Imperium’s growth accelerated in the third quarter. We went from approximately $8 million in assets deployed in paired liquidity pools (“LP”) at the end of Q2 to approximately $36 million today. The growth of our paired LP assets puts us in a strong position to exceed our $6 million gross profit target for the year.”

Launched in 2025, Imperium is BTCS’s DeFi business line, through which the Company generates revenue by actively deploying digital assets (currently ETH and stablecoins) into smart contract-based protocols that facilitate decentralized lending, borrowing, liquidity provisioning, and other financial activities. Rather than relying on a single approach, Imperium spans a range of evolving strategies. Unlike staking, which is primarily a yield play with protocol-set rewards and lock-up requirements, Imperium’s DeFi approach allows BTCS to dynamically allocate assets across protocols and networks based on prevailing market conditions, profit potential, and risk, positioning the Company to scale revenue and improve profitability.

“Base has grown into one of the largest Ethereum Layer-2 networks, with over $12 billion in on-chain assets today. We continue to see strong transaction volume and rising demand on Base, and that scale and activity make it a compelling environment for Imperium to pursue high-margin revenue,” said Ben Hunter, Chief Technology Officer of BTCS.

Integrating Base into Imperium’s operations extends the Company’s revenue-generating DeFi activities into an additional, widely used Ethereum Layer-2 ecosystem, further diversifying the Company’s footprint beyond Ethereum mainnet. The Company believes this integration supports its objective of driving high-margin, scalable revenue, as Imperium can generate and compound revenue across a broader set of opportunities. Base is one step in a broader roadmap: BTCS is actively evaluating additional strategies for Imperium that it believes may further scale the business.

About BTCS:

BTCS Inc. (“BTCS” or the “Company”), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and asset accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance (“DeFi”) and traditional finance (“TradFi”) mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking), Builder+ (block building), and Imperium (DeFi deployments), BTCS offers a unique opportunity for blockchain exposure, driven by recurring on-chain revenue generation and an Ethereum-focused strategy. Discover how BTCS offers exposure to Ethereum and its on-chain economy through the public markets at www.btcs.com.

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, but are not limited to, statements regarding the expansion of Imperium onto Base, growth in the Company’s deployed digital assets, revenue expectations (including from Imperium), profitability and margin targets (including the Company’s $6 million gross profit target for the year), the Company’s ability to generate and compound revenue across multiple networks and protocols, market positioning, business strategy, regulatory developments affecting digital assets, and expectations for digital asset markets. Words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “predict,” “intend,” “target,” “seek,” “positioned” or similar expressions identify forward-looking statements. These statements are based on current expectations and assumptions and are subject to risks and uncertainties, including volatility in digital asset markets, including the market price of ETH and other digital assets, and concentration risk from the Company’s Ethereum-first strategy; regulatory developments affecting digital assets and blockchain technology, including regulation of DeFi protocols and Layer-2 networks; competition in DeFi markets; operational risks associated with Imperium, including smart contract vulnerabilities, DeFi protocol failures, counterparty risks, impermanent loss and liquidity risks associated with DeFi lending, borrowing, and liquidity provision activities, and the Company’s reliance on third-party DeFi protocols; risks related to the Company’s use of leverage and collateralization requirements; the risk that the Company may not achieve its revenue or profitability targets, including the $6 million gross profit target; technological implementation challenges, cybersecurity risks, and potential loss or theft of digital assets; risks related to the Ethereum network and Layer-2 networks such as Base, including fluctuations in transaction volumes and blockspace demand, and changes in network protocols, consensus mechanisms, or gas fee structures; risks that the Company’s multi-chain expansion strategy may not produce the anticipated benefits; general economic and market conditions; and other risks set forth in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025. Undue reliance should not be placed on forward-looking statements, which speak only as of the date of this release. The Company expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

For more information, follow us on:

X: https://x.com/NasdaqBTCS
LinkedIn: https://www.linkedin.com/company/nasdaq-btcs
Facebook: https://www.facebook.com/NasdaqBTCS

Investor Relations:

Charles Allen – CEO
X: @Charles_BTCS
Email: ir@btcs.com

A Special Committee of independent directors carefully reviewed Forward’s all-stock proposal before determining it was not in the best interests of shareholders 

SkyAI reaffirms commitment to its Solana DAT strategy and continues to hold more than two million SOL with no debt

Board reiterates commitment to transparency and strong governance

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) — SkyAI, Inc. (Nasdaq: SKYA) (“SkyAI” or the “Company”), a financial technology company with a Solana digital asset treasury (“DAT”) that is building an agentic finance platform, today issued the following statement regarding a recent public letter from Forward Industries, Inc. (“Forward”).

SkyAI’s Board of Directors (the “Board”) remains committed to acting in the best interests of all shareholders. The Board believes shareholders should have the full facts and context as they consider the matters before them at the upcoming Annual Meeting.

The Special Committee thoroughly reviewed Forward’s acquisition proposal and determined it was not in the best interests of shareholders

The Board carefully evaluates opportunities that may enhance shareholder value. After receiving Forward’s unsolicited, non-binding, all-stock acquisition proposal in June, the Board established a Special Committee consisting entirely of independent directors to carefully evaluate the proposal.

The Special Committee, with the assistance of independent advisors, considered factors such as the terms and structure of the proposal, including its all-stock nature and associated risks and uncertainties, as well as SkyAI’s standalone prospects.

Following its review, the Special Committee unanimously concluded that Forward’s proposal was not in the best interests of shareholders and that continuing to execute SkyAI’s standalone strategy offered a more compelling opportunity for long-term value creation. The full Board has subsequently reached the same conclusion.

The Board stands by its decision and remains committed to guiding and overseeing SkyAI’s strategy for the benefit of all shareholders.

SkyAI reaffirms its commitment to its Solana DAT strategy

SkyAI continues to hold more than two million SOL as its primary treasury reserve asset. Nearly all of the Company’s SOL is staked with institutional validators, enabling SkyAI to participate directly in securing the Solana network while generating staking revenue. SkyAI currently intends that revenue from the DAT strategy will fund cash operating expenses including DAT operations, corporate expenses and R&D.

From the launch of its treasury strategy in August 2025 through June 30, 2026, SkyAI recognized more than $12 million in staking revenue, net of validator commissions. As of that date, the Company also held approximately $12.1 million in cash and stablecoins and had no outstanding debt. Over the ten epochs from August 23 to September 8, 2026, SkyAI’s Solana validator generated an annualized gross yield of 6.01% in SOL, compared with a stake-weighted average of 5.57% across all Solana validators over the same epochs¹.

The Company’s conviction in Solana extends beyond its treasury holdings. SkyAI is building its agentic finance platform on Solana and believes the network’s speed, cost structure, developer ecosystem, and growing application activity make it well positioned to support the next generation of on-chain financial and AI products.

Continued growth across the Solana ecosystem reinforces that conviction. Solana has led all blockchains in application revenue for nine consecutive quarters through the second quarter of 2026, and applications built on Solana generated more revenue in August than applications on any other blockchain.

SkyAI believes its combination of a substantial SOL treasury, staking participation, and technology development on Solana creates differentiated exposure to the continued growth of the ecosystem.

The Board is committed to strong governance and oversight

The Board recognizes the importance of effective governance and transparency. The Company has publicly disclosed its relationships and arrangements with its consultant and strategic advisor in prior filings. These agreements were reviewed by the Board, with the assistance of independent advisors, and were entered into by the Company on August 25, 2025, prior to the closing of the August 2025 private placement (the “PIPE”) on August 28, 2025.

The strategic advisor warrants issued to SOL Markets cover 6,321,367 shares, calculated as 10% of the shares issued in the PIPE. The approximately $101.3 million figure cited in Forward’s letter is not a cash payment to the strategic advisor; rather, it represents the grant-date accounting fair value required to be recognized under U.S. GAAP for the warrants issued in August 2025. The strategic advisor has not sold any shares or warrants of the Company and continues to hold its full position without any hedging instruments.

SkyAI’s related-party transactions policy requires Audit Committee approval of covered transactions involving directors, officers, 5% shareholders and their affiliates. The Board will continue to oversee related-party matters and act in the best interests of shareholders.

The Board will continue to evaluate the Company’s governance practices as SkyAI grows and evolves.

The 2026 Equity Incentive Plan aligns talent with long-term shareholder value and reflects market norms

SkyAI’s transformation from its legacy medical device business into a DAT and financial technology company requires new capabilities across digital assets, artificial intelligence, blockchain infrastructure, and financial services. Attracting and retaining that talent requires SkyAI to offer compensation that is competitive with other technology and DAT companies while aligning employees, executives, and directors with long-term shareholders.

In determining the size of the proposed 2026 Equity Incentive Plan, the Board considered the remaining capacity under the existing plan, anticipated hiring and retention requirements, projected future equity needs, and equity plan authorizations at comparable DAT companies and technology issuers. Importantly, the proposed authorization remains below the median equity incentive plan authorized by comparable DAT companies when measured on a fully diluted basis, which includes pre-funded warrants and other warrants exercisable at par value.

The Board believes the proposed plan represents a measured approach that allows SkyAI to attract and retain talent, aligns compensation with long-term shareholder value, and preserves cash for operations and execution of the Company’s strategy.

SkyAI’s Board and management are focused on unlocking value for all shareholders

Over the past year, SkyAI has undertaken a significant transformation. The Company has established a substantial Solana treasury, generated staking revenue from those assets, and is building an agentic finance platform.

The Board remains confident that the continued execution of the Company’s strategy will unlock significant value for shareholders.

The Board unanimously recommends that SkyAI shareholders vote FOR each of the Company’s director nominees and FOR the 2026 Equity Incentive Plan at the Annual Meeting on September 18, 2026.

YOUR VOTE IS IMPORTANT

To ensure your shares are represented at the Annual Meeting, please submit your vote TODAY: Vote “FOR” All of SkyAI’s Highly Qualified Nominees

If you have any questions or require any assistance with voting your shares, please call the Company’s proxy solicitor:

Advantage Proxy, Inc
P.O. Box 10904
Yakima, WA 98909
Attn: Karen Smith
Toll Free Telephone: (877) 870-8565
Main Telephone: (206) 870-8565
E-mail: ksmith@advantageproxy.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this release other than statements of historical fact are forward-looking statements, including statements regarding the Company’s strategy and product roadmap and the potential opportunities such initiatives may create. Forward-looking statements are based on current expectations, assumptions, and beliefs, and involve risks and uncertainties that could cause actual results to differ materially.

These risks and uncertainties include, among others: the Company’s ability to successfully execute its digital asset treasury and AI technology strategies; the price of SOL and the level of staking rewards; the outcome of the Annual Meeting and any further actions by Forward or other shareholders; and general market, economic, and business conditions. Additional risks are described in the “Risk Factors” section of the Company’s filings with the Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov.

Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise these statements, whether as a result of new information, future developments, or otherwise, except as required by law.

Important Additional Information and Where to Find It 

The Company has filed a definitive proxy statement with the SEC in connection with its solicitation of proxies for the Annual Meeting. Shareholders are able to obtain the Company’s proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies are also available at no charge at the Company’s website at https://www.skyai.co/investors/all-sec-filings.

Participants in the Solicitation

The Company, its directors and certain of its executive officers are deemed to be “participants” (as defined in Schedule 14A under the Exchange Act of 1934, as amended) in the solicitation of proxies from the Company’s shareholders in connection with matters to be considered at the Annual Meeting of shareholders. Information about the names of the Company’s directors and officers, and certain other individuals and their respective interests in the Company by security holdings or otherwise, and their respective compensation, is set forth in the Company’s Proxy Statement on Schedule 14A in connection with the Annual Meeting and the Company’s Annual Report on Form 10-K.  The Company has also engaged the services of Advantage Proxy, Inc. to solicit proxies from its shareholders.  

About SkyAI

SkyAI, Inc. (Nasdaq: SKYA), formerly Sharps Technology, Inc., is building Agentic Finance for the Global South that will combine stablecoin rails on Solana with AI to deliver financial access, education, and actionable intelligence to the billions of underbanked users across Asia, Latin America, and Africa. For additional information, please visit www.theskyai.co.

Media Contact
Edelman Smithfield
SkyAI@edelmansmithfield.com

^{_________________________________
1} Data: Trillium (trillium.so), per-epoch validator and network rewards, epochs 1021 to 1030 (August 23 to September 8, 2026), pulled September 9, 2026. Network figures are stake-weighted across all validators. Gross yields comprise inflation rewards, block rewards (priority fees) and MEV before validator commission.

RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden 

Additional Data and Updates on Regulatory Discussions Anticipated in 4Q 2026

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TN-401, Tenaya’s gene therapy candidate for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).

“RMAT designation underscores the continued recognition by regulators of the seriousness of PKP2-associated ARVC and the potential of TN-401 gene therapy to change the course of disease by addressing its underlying cause. This designation is supported by the encouraging interim data generated to date from our RIDGE-1 trial, which demonstrated clinically meaningful reductions in daily rates of PVCs and NSVTs, as well as a favorable tolerability profile,” said Faraz Ali, Chief Executive Officer of Tenaya Therapeutics. “Together with Fast Track and Orphan Drug designations, RMAT enhances our ability to engage with the FDA as we strive to advance TN-401 toward a pivotal trial in order to bring this potentially transformative treatment to patients as quickly as possible. We look forward to sharing additional data from RIDGE-1 in the fourth quarter and providing an update on our ongoing discussions with regulators regarding pivotal trial plans for TN-401.”

Tenaya’s RMAT application included data presented at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting in May 2026. Interim results from the RIDGE-1 clinical trial of TN-401 showed improvements in multiple electrical stability measures, including reduced rates of premature ventricular contractions (PVCs) and non-sustained ventricular tachycardias (NSVTs), two of the most frequently occurring forms of ventricular arrhythmias that characterize ARVC.

RMAT designation is an FDA expedited program intended to facilitate the development and review of regenerative medicine therapies for serious conditions where preliminary clinical evidence indicates the potential to address unmet medical needs. RMAT designation provides enhanced opportunities for interaction with the FDA, including early and ongoing guidance regarding clinical development, manufacturing and potential regulatory pathways, and it may provide eligibility for accelerated approval, priority review and rolling review.

About PKP2-Associated ARVC
Plakophilin-2 (PKP2) mutations are the most common genetic cause of arrhythmogenic right ventricular cardiomyopathy (ARVC, also known as arrhythmogenic cardiomyopathy or ACM), occurring in approximately 40 percent of the overall ARVC population. The prevalence of PKP2-associated ARVC is estimated at more than 70,000 people in the U.S. alone.

In PKP2-associated ARVC, mutations of the PKP2 gene results in insufficient expression of a protein needed for the proper functioning of the desmosomal complex that maintains physical connections and electrical signaling between heart muscle cells. As the desmosome structure degrades, cardiac muscle cells are replaced by fibrofatty tissue and electrical pulses in the heart become unstable, resulting in life potentially threatening heart rhythms. ARVC symptoms include arrhythmias, palpitations, lightheadedness, dizziness and fainting. It is typically diagnosed before age 40, and sudden cardiac arrest due to ventricular arrhythmia is frequently the first manifestation of disease. Current treatments include anti-arrhythmic medications, implantable cardioverter-defibrillators (ICDs) and ablation procedures, which do not address the underlying genetic cause of disease.

About TN-401 Gene Therapy and the RIDGE-1 Clinical Trial
TN-401 is an investigational AAV9-based gene therapy being developed for the treatment of ARVC due to mutations in the PKP2 gene. AAV9 was selected as the vector for delivery of Tenaya’s PKP2 gene therapy based on its extensive clinical and commercial safety record and demonstrated ability to target heart muscle cells. TN-401 has received Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration, as well as PRIME designation from the European Medicines Agency. Tenaya’s development of TN-401 is supported in part by a grant from the California Institute for Regenerative Medicine (CIRM).

The RIDGE-1 Phase 1b/2 clinical trial ClinicalTrials.gov (NCT06228924) of TN-401 in patients with PKP2-associated ARVC is a multi-center, open-label, dose escalation study being conducted in the U.S. and UK. RIDGE-1 is intended to assess the safety, tolerability and preliminary clinical efficacy of a one-time intravenous infusion of TN-401. RIDGE-1 seeks to enroll up to fifteen adults who have been diagnosed with PKP2-associated ARVC, have an ICD and are at increased risk for arrhythmias as determined by premature ventricular count (PVC) during screening. As part of its TN-401 development program, Tenaya is also conducting RIDGE ClinicalTrials.gov (NCT06311708), believed to be the largest natural history study of adults with PKP2-associated ARVC.

To learn more about gene therapy for ARVC and the RIDGE-1 clinical trial, please visit ARVCstudies.com.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM); TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC); and TN-301, a highly specific small molecule HDAC6 inhibitor with broad potential clinical utility in cardiac, metabolic and muscular conditions, including heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). Tenaya has employed a suite of integrated internal capabilities including modality agnostic target discovery and validation, to generate a portfolio of novel medicines based on genetic insights, aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Words such as “anticipated,” “potential,” “strive,” “look forward,” “may” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, the plan and related timing to share additional data from RIDGE-1 and provide an update on regulatory discussions regarding pivotal trial plans for TN-401; the potential for TN-401 gene therapy to change the course of PKP2-associated ARVC by addressing the underlying cause of disease; the potential development and regulatory review opportunities for TN-401 due to RMAT designation; Tenaya’s efforts to advance TN-401 toward a pivotal trial; and statements by Tenaya’s Chief Executive Officer. The forward-looking statements contained herein are based upon Tenaya’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: availability of data at the referenced time; the timing and progress of RIDGE-1 and Tenaya’s other ongoing clinical trials; the potential failure of TN-401 and Tenaya’s other product candidates to demonstrate safety and/or efficacy in clinical testing; the potential for the FDA and/or other regulatory agencies to conclude at any time that TN-401 may not have an appropriate risk/benefit profile; changes in Tenaya’s plans to develop and commercialize TN-401 and its other product candidates; the potential for RIDGE-1 clinical trial results to differ from preclinical, interim, preliminary, topline or expected results; risks associated with the process of discovering, developing and commercializing therapies that are safe and effective for use as human therapeutics; Tenaya’s ability to develop, initiate or complete preclinical studies and clinical trials, and obtain approvals, for any of its product candidates; Tenaya’s continuing compliance with applicable legal and regulatory requirements; Tenaya’s ability to raise any additional funding it will need to continue to pursue the clinical development of TN-401 and its other product candidates, as well as Tenaya’s general business plans; Tenaya’s reliance on third parties; Tenaya’s manufacturing, commercialization and marketing capabilities and strategy; the loss of key scientific or management personnel; competition in the industry in which Tenaya operates; Tenaya’s ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in Tenaya’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and future documents that Tenaya files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Tenaya assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com

Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com

Media
Wendy Ryan
Ten Bridges Communications
wendy@tenbridgecommunications.com